



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Kreye, P. et al ) Art Unit: 1614 U.S. Appln. No. : 10/692,060 ) Examiner: Confirmation No. : 7275 U.S. Filing Date : 10/23/2003 Title of Invention : Process for Preparing (R)-Salbutamol Attny. Docket No.: 1/1404US	
Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450	
September 20, 2004	
TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE S	TATEMENT
Sir:	
Transmitted herewith concerning the subject application is an Information D Statement under 37 C.F.R. §§1.56 and 1.97, as more specifically described by	visclosure nereinbelow.
1.97(b). This Statement is being filed: i) within three (3) mont date of a national application other than a continued prosecution application §1.53 (d); ii) within three (3) months of the date of entry of the national stag 37 C.F.R. §1.491 in an international application; iii) before the mailing of a on the merits; or iv) before the mailing of a first Office action after the filing continued examination under 37 C.F.R. §1.114.	under 33 C.F.R. se as set forth in first Office action
1.97(c). This Statement is being filed after the time period spectral C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.I. notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise prosecution in the application. This Statement is being accompanied by:	F.R. §1.113, ii) a
A statement as specified in 37 C.F.R. §1.97(e) [see below];	or
The fee set forth in 37 C.F.R. §1.17(p).	
The Commissioner is hereby authorized to charge pay \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account	yment of the nt No.

1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).
1.97(e).
Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
The fee set forth in 37 C.F.R. §1.17(p).
The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.
The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Andrea D. Small

Attorney for Applicant(s)

Reg. No. 54,859

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4816 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on September 20, 2004.

Andrea D. Small, Reg. No. 54,859

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. RADEMA Substitute for form 1449A/PTO Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Application Number** 10/692,060 Filing Date 10/23/2003 First Named Inventor Paul KREYE Art Unit 1614 **Examiner Name** 

(Use as many sheets as necessary) Attorney Docket Number 1/1404US

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-		-	
	<u> </u>	US-			CHILDRE, ALL MANISON AND CHILDREN AND CHILDRE CHILDREN AND CHILDREN AND CHILDREN AND CHILDREN AND CHILDREN AN
		US-			
	<b></b> -	US-	<del></del>		NAMES OF THE PARTY
		US-	HILBERT TO THE TOTAL CONTROL OF THE TOTAL CONTROL O		
		US-			WHAT I I I I I I I I I I I I I I I I I I I
	<u> </u>	US-			- Accessive
		US-			. SAUGURENT II I I I I I I I I I I I I I I I I I
		US-			
		US-			
		US-	wante no		
		US-			
		US-			Addition of the second
		US-	water and the second se		
		US-			
		US-	Muminamumier/State var on		Land to the state of the state
		US-			Constitution of the Consti
		US-			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
		WO 95/29146 A1	11/02/1995	Sepracor, Inc.		
•••••		WO 00/43345 A1	07/27/2000	Bl Pharma KG		
***************************************	<b>*</b>					
***************************************	<b>1</b>					
***************************************	<b>†</b>					

Examiner	<u> </u>	Date	
Signature		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO Application Number 10/692,060 Filing Date INFORMATION DISCLOSURE 10/23/2003 First Named Inventor STATEMENT BY APPLICANT Paul KREYE Art Unit 1614 (Use as many sheets as necessary) Examiner Name Sheet Attorney Docket Number 2 1/1404US

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1			
		SAKURABA, S. ET AL; Efficient Asymmetric Hydrogenation of Alfa-Amino Ketone Derivatives. A Highly Enantioselective Synthesis of Phenylephrine, Levamisole, Carnitine and Propranolol"; Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan; Bd. 43, Nr. 5, Pages 738-747		
		OIP E VEGOS		
	:	SEP 2 2 2004 B		
		·		
			<u> </u>	

Examiner Signature Date Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.